Archived Press

ProPhase Stock Quote

PRPH
Last
2.11
Change
0.01 (0.5%)

2016 ProPhase Labs Annual Report

ProPhase Labs to Release Third Quarter Results on Wednesday, November 9th

11-02-2011 17:45:15
Press Release

DOYLESTOWN, PA – November 2, 2011 - ProPhase Labs (NASDAQ: PRPH) announced today that financial results for the third quarter, ended September 30, 2011, will be released before the market opens on Wednesday, November 9th. A shareholder’s conference call will be held later that morning on November 9th, at 11:00am EST. ProPhase Labs Chairman and CEO, Ted Karkus, and COO/CFO Robert Cuddihy will provide a company overview including a review of activities and third quarter results. There will be a question and answer session following initial remarks.

 

The conference call will be webcast live at: http://us.meeting-stream.com/prophaselabsinc_110911 at 11:00 AM (EDT) on Wednesday, November 9, 2011.

 

Participants wishing to ask questions may access the live call by dialing (877) 217-6026 conference ID # 21014476. A replay of the conference call will be available for 90 days on the company website www.ProPhaseLabs.com.

 

###

 

About ProPhase Labs

 

ProPhase Labs is a diversified natural health medical science company. It is a leading marketer and manufacturer of the Cold-EEZE® family of lozenges clinically proven to significantly reduce the severity and duration of the common cold. Cold-EEZE customers include leading national retailers, chain food, drug and mass merchandise stores, wholesalers and distributors, as well as independent pharmacies. ProPhase Labs has several wholly owned subsidiaries including a manufacturing unit, which consists of an FDA registered facility to manufacture Cold-EEZE lozenges and fulfill other contract manufacturing opportunities. ProPhase also owns 50% of Phusion Laboratories LLC ("Phusion").  Phusion licenses a revolutionary proprietary technology that has the potential to improve the delivery and/or efficacy of many active ingredients or compounds.  Phusion will formulate and test products to exploit market opportunities within ProPhase’s robust OTC distribution channels. For more information visit us at www.ProPhaseLabs.com.

 

Press Only Contact:

Jenny Miranda

5W Public Relations

Tel: (212) 584-4295

jmiranda@5wpr.com

 

Investor Relations:

Ted Karkus

Chairman of the Board, CEO

(215) 345-0919 x0